Since GSDMB is frequently over-expressed in diverse cancer types [3], where usually associates with poor prognosis [3], the activation of GSDMB pro-cell death function has been previously explored as a novel therapeutic approach using two different methods: a) an antibody-based nanomedicine that seemed to activate the protein cytotoxic activity in breast cancer xenografts in vivo [14]; b) triggering the proteolytic cleavage of GSDMB NT pore-forming domain by lymphocyte Granzyme-A [8] via pharmacological activation (anti-PD-1) of the antitumor immunity response [8]. The gene discussed is GZMA; the disease is breast cancer.